Sulfamoxole
Title: Sulfamoxole
CAS Registry Number: 729-99-7
CAS Name: 4-Amino-N-(4,5-dimethyl-2-oxazolyl)benzenesulfonamide
Additional Names: N1-(4,5-dimethyl-2-oxazolyl)sulfanilamide; 2-(p-aminobenzenesulfonamido)-4,5-dimethyloxazole; 4,5-dimethyl-2-sulfanilamidooxazole; p-aminobenzenesulfonyl-2-amino-4,5-dimethyloxazole; sulfadimethyloxazole
Trademarks: Justamil (Anphar-Rolland); Sulfmidil (Tika); Sulfuno (Nordmark); Tardamide (Grñenthal)
Molecular Formula: C11H13N3O3S
Molecular Weight: 267.30
Percent Composition: C 49.43%, H 4.90%, N 15.72%, O 17.96%, S 12.00%
Literature References: Prepn: Loop et al., US 2809966 (1957 to Nordmark-Werke). Series of articles on antimicrobial activity, pharmacology and clinical efficacy of mixture with trimethoprim: Arzneim.-Forsch. 26, 595-684 (1976). Toxicity data: F. Lagler et al., ibid. 634.
Properties: Crystals, mp 193-194°. Soly in mg/100 ml at 20°: water 85; 0.01N HCl 163; 0.01N NaOH 196; methanol 2315; chloroform 240. uv max (4.91 mg/ml methanol): 210, 250, 270 nm (e 740, 546, 857). LD50 in mice, rats (g/kg): >10.0, >12.5 orally; 1.80, ~2.50 i.p. (Lagler).
Melting point: mp 193-194°
Absorption maximum: uv max (4.91 mg/ml methanol): 210, 250, 270 nm (e 740, 546, 857)
Toxicity data: LD50 in mice, rats (g/kg): >10.0, >12.5 orally; 1.80, ~2.50 i.p. (Lagler)
 
Derivative Type: Mixture with trimethoprim
CAS Registry Number: 57197-43-0
Additional Names: Co-trifamole
Manufacturers' Codes: CN-3123
Trademarks: Co-Fram (Abbott); Dibactil (Roemmers); Nevin (Grñenthal); Supristol (Gallier)
Properties: LD50 in mice, rats (g/kg): >12.0, 14.0 orally; 1.87, 2.00 i.p. (Lagler).
Toxicity data: LD50 in mice, rats (g/kg): >12.0, 14.0 orally; 1.87, 2.00 i.p. (Lagler)
 
Therap-Cat: Antibacterial.
Keywords: Antibacterial (Synthetic); Sulfonamides.

Others monographs:
2,2'-Dithiobis[benzothiazole]Penicillin FReductic AcidNorfloxacin
PrimeveroseMephosfolanMethopreneTrithiozine
LevomepateL-AsparaginaseNafcillinRuthenium Red
Docusate SodiumEthyl PhosphorochloriditeDeoxycholic AcidChromous Formate
©2016 DrugLead US FDA&EMEA